iQSTEL Wins Stockholder Nod to Tap $50M Equity Line and Ratify Toxic Convertible Deals

summarizeSummary

iQSTEL's majority stockholders greenlit exceeding Nasdaq's 19.99% cap, fully opening a $50M dilutive equity line, ratifying past toxic convertible issuances, and awarding new equity to executives.

check_boxKey Events · Financing and Capital Events · IQST

• Nasdaq 19.99% Cap Waived

  Stockholders approved issuances exceeding 19.99% of outstanding shares under the $50M M2B equity line and Series D Preferred Stock conversions, removing the last regulatory limit on massive dilution.

• Equity Line Unlocked

  The M2B equity line allows sales at a 6% discount to the lowest VWAP over six days; with the cap waived, iQSTEL can now draw down the full $50M commitment, potentially issuing millions of shares at depressed prices.

• Toxic Convertible Ratified

  The approval ratifies past and future Series D conversions under a 5x true-up ratio, which can multiply shares issued retroactively based on a 20% discount to the lowest VWAP, with a $1.00 floor.

• Executive Equity Grants

  CEO Leandro Iglesias and CFO Álvaro Quintana Cardona will receive 20,000 and 14,000 Series B Preferred Shares for FY2025, convertible into 425,000 common shares, adding to dilution.

auto_awesomeAnalysis · IQST · Technology

With stockholder approval now in hand, iQSTEL can breach Nasdaq's 19.99% issuance cap, unlocking a $50 million equity line with M2B Funding and ratifying past and future conversions of Series D Preferred Stock that carry a punishing 5x true-up ratio. The equity line lets the company sell shares at a 6% discount to the lowest VWAP, while the Series D true-up can retroactively multiply the share count at prices likely below market. This vote sweeps away the final regulatory hurdle to highly dilutive financing that could overwhelm existing holders. Adding to the pressure, the board granted executives 34,000 Series B Preferred Shares convertible into 425,000 common shares. With the company still under a going-concern cloud, this capital lifeline is critical for survival but brutal for current shareholders.